Skip to content

Study · Systematic review · 2023

2 results

Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.

Kovalic AJ, Gozar M, Da BL, Bernstein D, Satapathy SK

European journal of gastroenterology & hepatology17 Nov 2022Cited by 9 (Europe PMC)

PMID36468574 (opens in a new tab)DOI10.1097/meg.0000000000002463 (opens in a new tab)PepBankPUB-36468574
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of trials in NAFLD, semaglutide was among the most effective and statistically significant treatments for change in liver stiffness by vibration controlled transient elastography.

    In plain wordsIn a pooled analysis of trials in fatty liver disease, semaglutide was among the best treatments for liver stiffness.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedChange in liver stiffness measurement (VCTE)
    Study

    n: not reported in source

    Comparator
    Network of other treatments and placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Across the primary endpoint, firsocostat, semaglutide, montelukast, cilofexor plus firsocostat, obeticholic acid and diacerein (change in LSM via vibration controlled transient elastography), in addition to lubiprostone and pemafibrate (change in LSM via magnetic resonance elastography) were found t…
    3 context sentences
    Summary · context
    The primary endpoint was the absolute change in liver stiffness measurement (LSM) via elastography.
    Summary · context
    A comprehensive systematic review and frequentist random effects network meta-analysis was performed among randomized controlled trials reporting pharmacologic intervention in NAFLD.
    Summary · context
    Forty-five randomized controlled trials enrolling 6932 patients were identified for this network meta-analysis.
  2. 02HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of trials in NAFLD, semaglutide was among the most effective treatments compared with placebo for change in the ELF score.

    In plain wordsIn a pooled analysis of trials in fatty liver disease, semaglutide was among the best treatments compared with placebo for the ELF fibrosis blood score.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedChange in enhanced liver fibrosis (ELF) score
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, the following interventions were determined to be most effective as compared to placebo among secondary endpoints: saroglitazar, lubiprostone, and obeticholic acid (change in APRI); saroglitazar, semaglutide, firsocostat and cilofexor plus firsocostat (change in ELF); obeticholic acid and…
    3 context sentences
    Summary · context
    Secondary endpoints included changes in noninvasive serologic tests including APRI, fibrosis-4 index, NAFLD fibrosis score, enhanced liver fibrosis (ELF) and FibroTest (FibroSure in the USA).
    Summary · context
    A comprehensive systematic review and frequentist random effects network meta-analysis was performed among randomized controlled trials reporting pharmacologic intervention in NAFLD.
    Summary · context
    Forty-five randomized controlled trials enrolling 6932 patients were identified for this network meta-analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.